Clinical Trial Update: Daylight PDT for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL) [Phase 4]

View source ↗

Summary

Phase 4 multicenter trial comparing BF-200 ALA and MAL in daylight photodynamic therapy for actinic keratosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• BF-200 ALA (5-aminolevulinic acid (ALA) topical photosensitizer)
• MAL (methyl aminolevulinate)

Snippet

Sponsor: Joint Authority for Päijät-Häme Social and Health Care | Conditions: Actinic Keratosis, Natural Daylight Photodynamic Therapy | Phase 4 | Status: COMPLETED